Compare HQL & FTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HQL | FTH |
|---|---|---|
| Founded | 1992 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 539.1M | 507.8M |
| IPO Year | N/A | 2021 |
| Metric | HQL | FTH |
|---|---|---|
| Price | $17.81 | $9.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 16 |
| Target Price | N/A | ★ $56.15 |
| AVG Volume (30 Days) | 102.6K | ★ 672.4K |
| Earning Date | 01-01-0001 | 11-03-2026 |
| Dividend Yield | ★ 11.56% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.79 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $23.17 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.66 | $9.67 |
| 52 Week High | $22.67 | $42.14 |
| Indicator | HQL | FTH |
|---|---|---|
| Relative Strength Index (RSI) | 44.90 | 25.41 |
| Support Level | $17.13 | N/A |
| Resistance Level | $18.58 | $21.97 |
| Average True Range (ATR) | 0.67 | 2.02 |
| MACD | 0.04 | -0.61 |
| Stochastic Oscillator | 26.26 | 3.13 |
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.